CD19-话题@MedSci

#CD19#

61篇内容 | 2894人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416450, encodeId=05fe1416450cd, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响, objectType=article, longId=184476, objectId=09e41844e696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09e41844e696, replyNumber=0, likeNumber=36, createdTime=2019-12-11, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09e41844e696, moduleTitle=ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09e41844e696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416449, encodeId=6fde14164498f, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=病例分享 | CD19抗原丢失导致CAR-T治疗后快速进展, objectType=article, longId=182587, objectId=06d418258ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06d418258ee0, replyNumber=0, likeNumber=73, createdTime=2019-11-09, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06d418258ee0, moduleTitle=病例分享 | CD19抗原丢失导致CAR-T治疗后快速进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06d418258ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416448, encodeId=40e81416448ad, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL, objectType=article, longId=181713, objectId=584d181e139f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=584d181e139f, replyNumber=0, likeNumber=80, createdTime=2019-10-23, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=584d181e139f, moduleTitle=Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=584d181e139f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416447, encodeId=7a11141644e63, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Scand J Immunol：过敏性鼻炎患者中PD-1/PD-L1途径的阻断能够促进CD19+ CD25+ Bregs细胞凋亡和抑制IL-10的分泌, objectType=article, longId=181815, objectId=99801818158b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99801818158b, replyNumber=0, likeNumber=60, createdTime=2019-10-23, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99801818158b, moduleTitle=Scand J Immunol：过敏性鼻炎患者中PD-1/PD-L1途径的阻断能够促进CD19+ CD25+ Bregs细胞凋亡和抑制IL-10的分泌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99801818158b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416446, encodeId=9b271416446f1, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：既可缓解CD19 CAR T细胞细胞因子释放综合征，又不减弱抗白血病疗效, objectType=article, longId=181317, objectId=f54218131ead, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f54218131ead, replyNumber=0, likeNumber=75, createdTime=2019-10-17, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f54218131ead, moduleTitle=Blood：既可缓解CD19 CAR T细胞细胞因子释放综合征，又不减弱抗白血病疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f54218131ead)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416445, encodeId=5af71416445f6, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：耗竭TCRαβ+/CD19+细胞可有效预防移植物抗宿主病(GVHD)，同时降低对供体匹配度的要求, objectType=article, longId=180391, objectId=f6531803912c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6531803912c, replyNumber=0, likeNumber=77, createdTime=2019-10-04, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6531803912c, moduleTitle=Blood：耗竭TCRαβ+/CD19+细胞可有效预防移植物抗宿主病(GVHD)，同时降低对供体匹配度的要求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6531803912c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416444, encodeId=f0b7141644488, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失, objectType=article, longId=180381, objectId=e0141803814a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0141803814a, replyNumber=0, likeNumber=59, createdTime=2019-10-03, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0141803814a, moduleTitle=Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0141803814a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416443, encodeId=ca05141644328, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果, objectType=article, longId=180054, objectId=6917180054ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6917180054ef, replyNumber=0, likeNumber=62, createdTime=2019-09-27, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6917180054ef, moduleTitle=安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6917180054ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416442, encodeId=27da1416442c6, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：自体干细胞移植后予以CD19 CAT T细胞治疗非霍奇金淋巴瘤！, objectType=article, longId=174786, objectId=b2031e478629, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2031e478629, replyNumber=0, likeNumber=75, createdTime=2019-07-05, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2031e478629, moduleTitle=Blood：自体干细胞移植后予以CD19 CAT T细胞治疗非霍奇金淋巴瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2031e478629)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416441, encodeId=bfbf141644110, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=73, createdTime=2019-06-28, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416440, encodeId=381b1416440ca, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著, objectType=article, longId=168714, objectId=1c1a168e1418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c1a168e1418, replyNumber=0, likeNumber=102, createdTime=2019-06-20, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c1a168e1418, moduleTitle=2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c1a168e1418)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416439, encodeId=2dfc1416439c0, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=全球抗癌细胞疗法管线分析：1000多个疗法在研 CD19受欢迎, objectType=article, longId=168411, objectId=cefc16841123, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cefc16841123, replyNumber=0, likeNumber=67, createdTime=2019-06-15, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cefc16841123, moduleTitle=全球抗癌细胞疗法管线分析：1000多个疗法在研 CD19受欢迎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cefc16841123)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416438, encodeId=62d7141643884, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=喜讯连连！科济生物再获CD19靶向的CAR-T细胞的临床试验许可, objectType=article, longId=161587, objectId=a4cf16158eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4cf16158eac, replyNumber=0, likeNumber=63, createdTime=2019-03-04, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4cf16158eac, moduleTitle=喜讯连连！科济生物再获CD19靶向的CAR-T细胞的临床试验许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4cf16158eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416437, encodeId=b4b7141643e10, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期, objectType=article, longId=159703, objectId=2590159e03b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2590159e03b3, replyNumber=0, likeNumber=67, createdTime=2019-02-11, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2590159e03b3, moduleTitle=Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2590159e03b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416436, encodeId=c99d141643670, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗, objectType=article, longId=155389, objectId=074b15538986, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=074b15538986, replyNumber=0, likeNumber=74, createdTime=2018-12-10, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=074b15538986, moduleTitle=Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=074b15538986)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416435, encodeId=b4dd1416435a4, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：预注射多功能的抗CD19的嵌合抗原受体T细胞可改善NHL患者的临床预后, objectType=article, longId=140802, objectId=f297140802b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f297140802b9, replyNumber=0, likeNumber=74, createdTime=2018-06-16, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f297140802b9, moduleTitle=Blood：预注射多功能的抗CD19的嵌合抗原受体T细胞可改善NHL患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f297140802b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416434, encodeId=31eb14164340d, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：CD19/CD3双特异性抗体为慢性淋巴细胞白血病患者，特别是依鲁替尼耐药的患者，带来新的希望, objectType=article, longId=137882, objectId=562213e882e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=562213e882e1, replyNumber=0, likeNumber=63, createdTime=2018-05-13, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=562213e882e1, moduleTitle=Blood：CD19/CD3双特异性抗体为慢性淋巴细胞白血病患者，特别是依鲁替尼耐药的患者，带来新的希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=562213e882e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416433, encodeId=b8f31416433cf, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood:CD19 CAR-T疗法引发脓毒症随意使用如同与虎谋皮？, objectType=article, longId=131530, objectId=aaec1315301a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaec1315301a, replyNumber=0, likeNumber=53, createdTime=2018-03-07, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaec1315301a, moduleTitle=Blood:CD19 CAR-T疗法引发脓毒症随意使用如同与虎谋皮？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaec1315301a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416432, encodeId=d6611416432d6, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？, objectType=article, longId=130441, objectId=33e2130441cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e2130441cc, replyNumber=0, likeNumber=61, createdTime=2018-02-25, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e2130441cc, moduleTitle=Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e2130441cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416431, encodeId=832614164315e, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Leukemia：CD19靶向的CAR-T细胞有望安全有效的治愈难治性复发性急性B淋巴细胞白血病！, objectType=article, longId=125530, objectId=ba02125530b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba02125530b8, replyNumber=0, likeNumber=115, createdTime=2018-01-06, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba02125530b8, moduleTitle=Leukemia：CD19靶向的CAR-T细胞有望安全有效的治愈难治性复发性急性B淋巴细胞白血病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba02125530b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD19

2020-05-29

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响

2019-12-11

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

病例分享 | CD19抗原丢失导致CAR-T治疗后快速进展

2019-11-09

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL

2019-10-23

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Scand J Immunol：过敏性鼻炎患者中PD-1/PD-L1途径的阻断能够促进CD19+ CD25+ Bregs细胞凋亡和抑制IL-10的分泌

2019-10-23

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：既可缓解CD19 CAR T细胞细胞因子释放综合征，又不减弱抗白血病疗效

2019-10-17

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：耗竭TCRαβ+/CD19+细胞可有效预防移植物抗宿主病(GVHD)，同时降低对供体匹配度的要求

2019-10-04

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Sci tranal med：BAFF-R靶向CAR T细胞疗法可克服B细胞恶性肿瘤的CD19抗原缺失

2019-10-03

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果

2019-09-27

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：自体干细胞移植后予以CD19 CAT T细胞治疗非霍奇金淋巴瘤！

2019-07-05

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解

2019-06-28

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著

2019-06-20

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

全球抗癌细胞疗法管线分析：1000多个疗法在研 CD19受欢迎

2019-06-15

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

喜讯连连！科济生物再获CD19靶向的CAR-T细胞的临床试验许可

2019-03-04

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期

2019-02-11

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗

2018-12-10

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：预注射多功能的抗CD19的嵌合抗原受体T细胞可改善NHL患者的临床预后

2018-06-16

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：CD19/CD3双特异性抗体为慢性淋巴细胞白血病患者，特别是依鲁替尼耐药的患者，带来新的希望

2018-05-13

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood:CD19 CAR-T疗法引发脓毒症随意使用如同与虎谋皮？

2018-03-07

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？

2018-02-25

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Leukemia：CD19靶向的CAR-T细胞有望安全有效的治愈难治性复发性急性B淋巴细胞白血病！

2018-01-06

科室
- - 订阅+
  - 更多科室
工具
服务